Current Report Filing (8-k)
September 07 2017 - 7:01AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 7, 2017
SYNTHETIC BIOLOGICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
001-12584
|
|
13-3808303
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File No.)
|
|
(I.R.S. Employer Identification No.)
|
9605 Medical Center Drive, Suite 270
Rockville, MD 20850
(Address of principal executive offices
and zip code)
Registrant’s telephone number, including
area code: (301) 417-4364
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
|
|
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Synthetic Biologics, Inc. (the “Company”)
will be making several investor presentations over the next several weeks, including a presentation at the 2017 Rodman & Renshaw
Global Investment Conference on Tuesday, September 12, 2017, in New York, New York. In connection with the presentations, the Company
intends to discuss the slide presentation attached as Exhibit 99.1 hereto, which is incorporated herein by reference.
The slide presentation attached as Exhibit
99.1 to this Report includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995,
as amended, indicating that certain statements contained in the slide presentation or in the press release are “forward-looking”
rather than historical.
The Company undertakes no duty or obligation
to update or revise information included in this Report or any of the Exhibits.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 7, 2017
|
SYNTHETIC BIOLOGICS, INC.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/ Steven Shallcross
|
|
|
Name: Steven Shallcross
|
|
|
Title: Chief Financial Officer
|
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Apr 2023 to Apr 2024